3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Lymphoma, Follicular
1
Lymphoma
1
Interventions
Cyclophosphamide
344
Rituximab
309
Vincristine
159
venetoclax
156
Doxorubicin
156
fludarabine
153
Specimen Handling
152
Prednisone
150
Biopsy
122
Magnetic Resonance Spectroscopy
117
obinutuzumab
116
Lenalidomide
110
Dexamethasone
106
Cytarabine
100
ibrutinib
96
Etoposide
94
fludarabine phosphate
87
Methotrexate
86
acalabrutinib
80
zanubrutinib
73
Bendamustine Hydrochloride
72
pembrolizumab
63
blinatumomab
63
CT-P10
61
Gemcitabine
52
glofitamab
45
Nivolumab
45
Calcium Dobesilate
45
prednylidene
43
Mercaptopurine
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
1-dodecylpyridoxal
×
Lymphoid
×
1 year
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled